![]() Compared with the use of midazolam, the utilization of remimazolam resulted in an increase in procedure success rate, a reduction in the application of rescue medication (OR = 13.58, 95% CI: 3.46–53.28), a decrease in time to recovery, and a better cognitive recovery of Hopkins Verbal Learning Test-Revised (WMD = 5.22, 95% CI: 2.88–7.55). Results: A total of five randomized controlled trials with 1,248 participants were included. We performed meta-analysis, trial sequential analysis (TSA), and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology for judging the certainty of evidence (CoE). Materials and Methods: The study protocol was registered (doi: 10.37766/inplasy20), and six databases were searched. ![]() However, prior trials and the participants they enrolled were limited.Īim: In this meta-analysis, we investigated the effectiveness and adverse events (AEs) of remimazolam during procedural sedation. Remimazolam has been approved for procedural sedation by the US Food and Drug Administration in 2020. 4Education Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwanīackground: Remimazolam is a new ultrashort-acting benzodiazepine.3Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. ![]() 2Department of Anesthesiology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.1Department of Anesthesiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.Bo-Jyun Jhuang 1 †, Bo-Han Yeh 2 †, Yen-Ta Huang 3 * and Pei-Chun Lai 4 * ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |